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Antithrombotic drugs are widely used for a variety of indica-
tions to prevent arterial and venous thrombosis. When anti-
thrombotic drugs are discontinued in the days before a surgi-
cal procedure, the risk for perioperative bleeding may de-
crease, whereas the risk of thromboembolic events rises. The
balancing of these risks remains an ongoing challenge for the
perioperative healthcare professional.
The risk for perioperative bleeding when antithrombotic
therapy is continued is determined by the type of surgery,
patient comorbidities and the type of anticoagulation therapy
[1]. Bleeding, and the consequent transfusion of blood prod-
ucts, are both independently associated with increased mor-
bidity and mortality [2]. Moreover, the location of periopera-
tive bleeding is an important contributing factor to outcome,
as it may cause serious complications in vital organs, and be
difficult to control.
Similarly, thromboembolic events may lead to complica-
tions such as pulmonary emboli, myocardial infarction or
cerebral vascular events, all contributing to an unfavourable
patient outcome. The risk for thrombotic events is based on
the indication for anticoagulation therapy and patient charac-
teristics, and increases in case of a surgical intervention [3].
Current guidelines assess the risk of thromboembolic
events by treatment indication, and compare these with in-
creased bleeding risks when anticoagulant therapy is
continued. Yet, perioperative management of antithrombotic
drugs remains controversial, as there is only limited evidence
available for the right therapeutic decision. Moreover, studies
investigating the risk of (dis)continuation of antithrombotic
drugs frequently use different treatment protocols and defini-
tions for bleeding and thromboembolic processes, resulting in
ambiguous results.
The PRAGUE-14 registry gives more insight into the
choice between the two evils in patients with cardiovascular
disease [4]. Patients continuing anticoagulant drugs had twice
as many bleeding events (13.3 %) compared with
thrombotic events (7.6 %). However, these bleeding
events led 10 times less often to death: 0.3 % from
bleeding versus 3.0 % as a result of thrombotic events.
This suggests that the increased risk for perioperative
bleeding resulting from continuation of antithrombotic
drugs seems to be manageable, whereas thromboembolic
events have serious consequences.
Despite the interesting conclusions of the PRAGUE-14
study, the article fails to show important information that
might be required to draw the right conclusions. First, while
it is known that the impact of cessation of antithrombotic
therapy partly depends on the preoperative health status of
the patient, the authors refrained from presenting data on the
specific interaction between preoperative comorbidities and
the decision to stop antithrombotic therapy, in particular in
light of a bridging protocol. For instance, the authors suggest
in the discussion that previous percutaneous coronary inter-
vention with coronary stent implantation is an independent
risk factor for perioperative complications. However, it is
unclear from their study whether they included patients with
a coronary stent who stopped antithrombotic therapy before
surgery, which may have a deleterious effect on outcome,
leading to myocardial infarction and mortality. This informa-
tion could be provided if the authors performed a specific
M. I. Meesters : C. Boer (*)
Department of Anaesthesiology, Institute for Cardiovascular
Research, VU University Medical Centre, De Boelelaan 1117, 1081
HVAmsterdam, the Netherlands
e-mail: c.boer@vumc.nl
Neth Heart J (2014) 22:370–371
DOI 10.1007/s12471-014-0580-6
analysis of the interaction between cessation of antithrombotic
therapy and specific preoperative comorbidities. Moreover, it
is unclear whether patients were subjected to a bridging pro-
tocol to prevent preoperative and postoperative thrombotic
complications.
Secondly, different antithrombotic drugs exert a different
impact on the risk for thrombosis or bleeding, and this risk is
subsequently modulated by patient health status and the treat-
ment regime. For instance, the recent randomised controlled
POISE-2 trial, which is referred to in the discussion section of
the PRAGUE-14 study, showed that the use of aspirin before
surgery and throughout the early postsurgical period had no
effect on mortality, but increased the risk of major bleeding
with a hazard ratio of 1.23 [5]. Interestingly, there was no
difference in mortality or major complications between pa-
tients who were already using aspirin before surgery, or started
on aspirin for study purposes. However, a closer evaluation of
the supplementary data of the POISE-2 trial shows that pa-
tients who were already on aspirin before surgery did not have
an increased risk of bleeding, while patients who started on
aspirin therapy before surgery showed a higher prevalence of
major haemorrhage. These data suggest that it is complex to
provide specific evidence for the benefits or disadvantages of
antithrombotic drug cessation before surgery, and that the
conclusions that are drawn from these studies should be
considered in light of distinct circumstantial aspects.
In order to change the current guidelines and to provide
practical guidance for the perioperative healthcare profession-
al, more studies are required that specifically focus on the
cessation or continuation of one antithrombotic drug in a more
uniform surgical patient population. However, due to its re-
flection of daily practice, data obtained from large patient
registries such as PRAGUE-14 may particularly be used to
generate relevant hypotheses and study algorithms for future
trials.
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